These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 37086699)
1. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Duan Y; Yu T; Jin L; Zhang S; Shi X; Zhang Y; Zhou N; Xu Y; Lu W; Zhou H; Zhu H; Bai S; Hu K; Guan Y Eur J Med Chem; 2023 Jun; 254():115367. PubMed ID: 37086699 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment. Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer. Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387 [TBL] [Abstract][Full Text] [Related]
4. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment. Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982 [TBL] [Abstract][Full Text] [Related]
6. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing. Li Z; Qin T; Li Z; Zhao X; Zhang X; Zhao T; Yang N; Miao J; Ma J; Zhang Z Eur J Med Chem; 2021 Dec; 225():113778. PubMed ID: 34416665 [TBL] [Abstract][Full Text] [Related]
7. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309 [TBL] [Abstract][Full Text] [Related]
8. Discovery of the antitumor activities of a potent DCN1 inhibitor compound 383 targeting LSD1 in gastric cancer. Song Z; Gao K; Asmamaw MD; Liu YJ; Zheng YC; Shi XJ; Liu HM Eur J Pharmacol; 2022 Feb; 916():174725. PubMed ID: 34953802 [TBL] [Abstract][Full Text] [Related]
9. A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo. Li YR; Liu FF; Liu WB; Zhang YF; Tian XY; Fu XJ; Xu Y; Song J; Zhang SY Biochem Pharmacol; 2022 Jul; 201():115070. PubMed ID: 35526597 [TBL] [Abstract][Full Text] [Related]
10. 6-Heterocyclic carboxylic ester derivatives of gliotoxin lead to LSD1 inhibitors in gastric cancer cells. Shan L; Li Z; Chen H; Ge M; Sun Y; Sun Y; Li Y; Li H; Fu L; Liu H Bioorg Chem; 2023 Feb; 131():106150. PubMed ID: 36508940 [TBL] [Abstract][Full Text] [Related]
11. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening. Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers. Yuan XY; Song CH; Liu XJ; Wang X; Jia MQ; Wang W; Liu WB; Fu XJ; Jin CY; Song J; Zhang SY Eur J Med Chem; 2023 Apr; 252():115281. PubMed ID: 36940611 [TBL] [Abstract][Full Text] [Related]
13. Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia. Li Y; Sun Y; Zhou Y; Li X; Zhang H; Zhang G J Enzyme Inhib Med Chem; 2021 Dec; 36(1):207-217. PubMed ID: 33307878 [TBL] [Abstract][Full Text] [Related]
14. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. Zheng YC; Duan YC; Ma JL; Xu RM; Zi X; Lv WL; Wang MM; Ye XW; Zhu S; Mobley D; Zhu YY; Wang JW; Li JF; Wang ZR; Zhao W; Liu HM J Med Chem; 2013 Nov; 56(21):8543-60. PubMed ID: 24131029 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors. Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992 [TBL] [Abstract][Full Text] [Related]
17. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy. Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors. Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389 [TBL] [Abstract][Full Text] [Related]
19. Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors. Li C; Su M; Zhu W; Kan W; Ge T; Xu G; Wang S; Sheng L; Gao F; Ye Y; Wang J; Zhou Y; Li J; Liu H J Med Chem; 2022 Mar; 65(5):4335-4349. PubMed ID: 35200034 [TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. Dong H; Yin H; Zhao C; Cao J; Xu W; Zhang Y Molecules; 2019 Jun; 24(13):. PubMed ID: 31261881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]